REGENXBIO

REGENXBIO is a clinical-stage biotechnology company. The company's product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; and RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is for the treatment of homozygous familial hypercholesterolemia.
  • TickerRGNX
  • ISINUS75901B1070
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
RGNX REGENXBIO (Health Care)

Regenxbio Inc: 2 directors sold/sold after exercising options

Two Directors at Regenxbio Inc sold/sold after exercising options 29,000 shares at between 50.000USD and 50.009USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is r...

RGNX REGENXBIO (Health Care)

Regenxbio Inc: 2 directors sold/sold after exercising options

Two Directors at Regenxbio Inc sold/sold after exercising options 29,000 shares at between 50.000USD and 50.009USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is r...

RGNX REGENXBIO (Health Care)

Regenxbio Inc: 2 directors sold/sold after exercising options

Two Directors at Regenxbio Inc sold/sold after exercising options 29,000 shares at between 50.000USD and 50.009USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is r...

RGNX REGENXBIO (Health Care)

Regenxbio Inc: 2 directors sold/sold after exercising options

Two Directors at Regenxbio Inc sold/sold after exercising options 29,000 shares at between 50.000USD and 50.009USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is r...

RGNX REGENXBIO (Health Care)

Regenxbio Inc: 2 directors sold/sold after exercising options

Two Directors at Regenxbio Inc sold/sold after exercising options 29,000 shares at between 50.000USD and 50.009USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is r...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch